DSG3 and pemphigus: Since efgartigimod treatment efficiently rescues the loss of keratinocyte adhesion upon anti-Dsg3 antibody and PV IgG treatment, our data strongly support the use of efgartigimod in the treatment of PV and suggest that stabilization of keratinocyte adhesion may present a novel treatment paradigm for pemphigus.